Pharmaron released its interim results, with a profit attributable to shareholders of 701 million yuan, a year-on-year decrease of 37%
I'm PortAI, I can summarize articles.
Pharmaron released its interim results for the period ending June 30, 2025, with revenue of 6.441 billion yuan, a year-on-year increase of 14.93%; profit attributable to shareholders was 701 million yuan, a year-on-year decrease of 37%. The basic earnings per share were 0.3984 yuan. The company stated that although the main business continued to improve, the net profit decreased by 37% compared to the same period last year due to significant investment gains from the disposal of PROTEOLOGIX, INC. shares in the previous year
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments